NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB) today announced the prioritization of its portfolio and a 45% workforce reduction to focus resources on its Phase 2-ready ...
Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and ...
(RTTNews) - Clinical-stage biotechnology company Rallybio Corporation (RLYB), Tuesday announced portfolio prioritization plan that reduces its workforce by 45% and extends its cash runway into ...
- Phase 1 study of CNTY-101, Company's lead candidate targeting CD19, in relapsed/refractory B-cell lymphoma remains on track; No impact to partnered programs with Bristol Myers Squibb - PHILADELPHIA, ...
Realigning resources to focus on clinical advancement of Selected TIL therapy Reducing employee headcount by approximately 60% Streamlining operations with cash runway expected to extend into 2Q 2026 ...
Givastomig: a Claudin 18.2 ("CLDN18.2") x 4-1BB bispecific antibody, will be the lead clinical program following the Company's portfolio prioritization The Company has completed enrollment of a dose ...
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment ...
COPENHAGEN, Denmark, December 29, 2025--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback